Kee D. Nam

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancer.

Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancer.

Journal: International journal of molecular medicine

Published: August 11, 2025

C‑terminal HSP90 inhibitor NCT‑58 impairs the cancer stem‑like phenotype and enhances chemotherapy efficacy in TNBC.

C‑terminal HSP90 inhibitor NCT‑58 impairs the cancer stem‑like phenotype and enhances chemotherapy efficacy in TNBC.

Journal: Oncology reports

Published: July 14, 2025

Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer.

Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer.

Journal: Experimental hematology & oncology

Published: April 14, 2025

The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer.

The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer.

Journal: Theranostics

Published: December 14, 2023

Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR.

Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 28, 2023

Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase.

Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase.

Journal: Cellular and molecular life sciences : CMLS

Published: August 19, 2022

β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features.

β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features.

Journal: Cancer cell international

Published: August 02, 2022

The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells.

The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells.

Journal: Cell death discovery

Published: August 16, 2021

A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response.

A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response.

Journal: Oncogene

Published: June 03, 2021

(E)-N-(3,3-Di-phenyl-allyl-idene)naph-thal-en-1-amine.

(E)-N-(3,3-Di-phenyl-allyl-idene)naph-thal-en-1-amine.

Journal: Acta crystallographica. Section E, Structure reports online

Published: May 09, 2013

(E)-N-[(E)-3-(4-Nitro-phen-yl)allyl-idene]naphthalen-1-amine.

(E)-N-[(E)-3-(4-Nitro-phen-yl)allyl-idene]naphthalen-1-amine.

Journal: Acta crystallographica. Section E, Structure reports online

Published: February 28, 2013

Showing 1-11 of 11

Last Updated: 09/26/2026